Suggestions
Freddy Nguyen
Physician Scientist Innovator - MIT Fellow - Mt Sinai Path Resident - Rice Alum - UIUC Alum - Optics/Imaging - Nanotechnology - Healthcare Innovation - Health Equity - Physician Scientist Pipeline - Transfusion Medicine
Freddy T. Nguyen, MD, PhD, is a Research Fellow at the Massachusetts Institute of Technology (MIT) and the CEO and Co-Founder of Nine Diagnostics.1 His research focuses on advancing functional precision medicine through the development of new technologies leveraging photonics and nanotechnologies.1
Dr. Nguyen's academic background is extensive. He earned his Ph.D. in Chemistry from the University of Illinois at Urbana-Champaign and his M.D. from the College of Medicine at the University of Illinois at Chicago.1 He also holds a B.S. in Chemistry and B.A. in Mathematics from Rice University.1
His career has included positions such as:
- Transfusion Medicine Fellow at Dartmouth
- Pathology Resident and Chief Resident at Mount Sinai Hospital
- Arnold O. Beckman Postdoctoral Fellow at MIT
- In Vivo Microscopy Fellow at the Wellman Center for Photomedicine at Massachusetts General Hospital1
Dr. Nguyen is actively involved in healthcare innovation and entrepreneurship. He has been a co-director of MIT Hacking Medicine, co-founder and co-director of the MIT COVID-19 Challenge, and co-founder and co-director of the MIT Hacking Racism Challenge.1
Recently, Dr. Nguyen's company, Nine Diagnostics, has achieved notable success:
- Selected for Merck Digital Sciences Studio Cohort 3 (November 14, 2024)2
- Won Novo Nordisk Golden Ticket for LabCentral Residency (September 19, 2024)2
Dr. Nguyen is also actively engaged in research on the physician-scientist pipeline at MIT, collaborating with other professionals in the field.1
Highlights
#Disparities in clinical studies of #AI enabled applications from a global perspective
Study finds that “leading countries and authors are primarily from high-income and upper-middle-income countries.”
“The limited representation of lower-middle-income and low-income countries is concerning since these countries may have different disease profiles and are, therefore, unable to benefit from existing research.”
“Moreover, the presence of gender disparities in clinical studies could lead to potential health inequalities.”
By Rui Yang, Sabarinath Vinod Nair, Yuhe Ke, Danny D’Agostino, Mingxuan Liu, Yilin Ning, Nan Liu
Nature Portfolio Digital Medicine #medicine #health #equity #research
A highlight of #Massachusetts Delegation Trip to#Netherlands is the cutting edge #innovation translated into new startups!
Thanks to Dutch companies who hosted us and to the Massachusetts companies for sharing your advances last week!
#medicine #biotech #biotechnology #healthcare
Koenraad Wiedhaup - Co-Founder and CEO at Leyden Labs Daniel de Boer - CEO at ProQR Therapeutics, Sheila Sponselee, Jurriaan Dekkers, rene beukema Minmin Yen, Ph.D., MPH (she/her) - CEO and Co-Founder at PhagePro Daniel Fischer - President and CEO at Tevard Biosciences Stan Wang, MD, PhD - CEO and Founder at Thymmune Therapeutics June Park, Ph.D. - CEO at siRNAgen Therapeutics Eva van Rikxoort, PhD - CEO and Founder at Thirona
#biotech #biotechnology #entrepreneurship #healthcare #medicine #health The Termeer Foundation Massachusetts Institute of Technology MIT Healthcare Innovation MIT linQ MIT Institute for Medical Engineering and Science (IMES) Netherlands Innovation Network in Boston Embassy of the Kingdom of the Netherlands in the USA hollandbio MOITI Massachusetts Office of International Trade and Investment
